Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Advertising & Marketing

Sales

Legal & Regulatory

Acquisition & Integration

Goodwill impairment

Restructuring costs

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Teladoc

Teladoc Health, Inc. engages in the provision of telehealthcare services using a technology platform via mobile devices, the Internet, video and phone. Its portfolio of services and solutions covers medical subspecialties from non-urgent, episodic needs like flu and upper respiratory infections, to chronic, complicated medical conditions like cancer and congestive heart failure. The company was founded on June 13, 2002, by George Byron Brooks and Gary Wald and is headquartered in Purchase, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Teladoc reports solid Q4 growth, eyes revenue optimization strategies

Teladoc's Q4 performance showed revenue growth and margin focus, with BetterHelp contributing significantly to profitability.
The company's strategic focus on virtual care expansion and revenue optimization positions Teladoc for continued success in the healthcare market.
While facing internal restructuring challenges, Teladoc's emphasis on growth drivers and operational efficiency presents opportunities for future growth and market leadership.

Teladoc Health excels in Q1, eyes growth and efficiency

Teladoc Health's Q1 performance was strong, with revenue exceeding expectations.
The company is focused on efficiency, innovation, and driving value in virtual care.
BetterHelp segment showed growth and stability, with improving margins expected.
Opportunities exist to capitalize on ad pricing stability and consumer behavior trends.

Teladoc surpasses revenue expectations, focuses on innovation and growth

Teladoc's Q2 performance exceeded expectations, with strong revenue growth and improved margins in both segments. The company's strategic focus on whole-person care, weight management, and AI enhancements positions it well for future growth. Challenges include managing drug costs and private company valuations, while opportunities lie in virtual care demand and strategic M&A.
Teladoc's financial strength, commitment to innovation, and focus on efficiency improvements are key strengths driving its performance. The company's ability to navigate challenges and capitalize on opportunities in the evolving healthcare landscape underscores its resilience and growth potential.

Teladoc Health surpasses Q3 expectations, eyes margin expansion in '24

Teladoc Health's Q3 performance exceeded expectations, driven by revenue growth and margin improvements.
The company is focused on enhancing cost efficiencies, profitability, and driving margin expansion.
Stable pricing environment and strong client demand present opportunities for future growth.
Operational review and strategic initiatives position Teladoc for continued success in the healthcare sector.

Teladoc reports robust 2023 earnings, eyes growth amid marketing challenges

Teladoc delivered strong financial performance in 2023 with notable growth in adjusted EBITDA and revenue. The company faces challenges in BetterHelp marketing yields and delayed consumer engagement efforts.
However, Teladoc's strategic strengths lie in its long-term outlook for revenue growth, margin expansion, and cost-saving initiatives. Opportunities exist in optimizing sales force structure and capital deployment for future growth.
Overall, Teladoc's focus on profitability, growth optimization, and strategic capital allocation positions it well for sustained success in the telehealth industry.

Teladoc Health reports solid Q1 performance amidst revenue challenges

Teladoc Health's Q1 2024 performance showcased revenue growth in Integrated Care but challenges in BetterHelp segment revenue and margin management.
The company's financial strength, product portfolio, and cost initiatives position it well for growth opportunities and strategic market positioning.
Addressing challenges in ad spend management and focusing on international market efficiency are key to unlocking growth potential and improving financial performance.
Overall, Teladoc's performance, strengths, challenges, and opportunities reflect a dynamic landscape with strategic focus on sustainable growth and operational efficiency.

Teladoc Health reports Q2 revenue dip, EBITDA growth; addresses challenges

Teladoc Health's Q2 2024 performance showed mixed results with revenue decline but EBITDA growth. The company is leveraging strengths in patient safety and technology while addressing challenges in customer acquisition costs. Opportunities lie in operational efficiency, insurance coverage access, and international expansion.

Teladoc Health reports Q3 revenue decline but strategic growth

Teladoc Health's Q3 2024 performance reflects mixed results with revenue decline but strategic growth in the Integrated Care segment.
The company's focus on customer-centric strategies, technology, and clinical excellence positions it well for future success and market leadership.
Challenges in revenue decline and expense management require Teladoc Health to balance short-term financial performance with long-term growth objectives.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Teladoc Health, Inc. engages in the provision of telehealthcare services using a technology platform via mobile devices, the Internet, video and phone. It operates through the following segments: Teladoc Health Integrated Care, BetterHelp, and Others. The Teladoc Health Integrated Care segment offers virtual medical services. The BetterHelp segment includes virtual mental health and other wellness services. The company was founded in June 2002, by George Byron Brooks, Michael Gorton, and Gary Wald and is headquartered in Purchase, NY.

Teladoc Health, Inc. (NYSE:TDOC ) Q2 2024 Earnings Conference Call July 31, 2024 4:30 PM ET Company Participants Chuck Divita - Chief Executive Officer Mala Murthy - Chief Financial Officer Michael Minchak - Head of Investor Relations Conference Call Participants Lisa Gill - J.P. Morgan Stephanie Davis - Barclays Jess Tassan - Piper Sandler Jailendra Singh - Truist Securities Richard Close - Cannacord Genuity Elizabeth Anderson - Evercore ISI Sarah James - Cantor Fitzgerald Sean Dodge - RBC Capital Markets Charles Rhyee - TD Cowen Michael Cherny - Leerink Partners Daniel Grosslight - Citi Operator Hello all, and welcome to Teladoc Health Second Quarter 2024 Earnings Call.

Teladoc Health, Inc. (TDOC) Q2 2024 Earnings Call Transcript

Although the revenue and EPS for Teladoc (TDOC) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Teladoc (TDOC) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

Teladoc (TDOC) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.36. This compares to loss of $0.40 per share a year ago.

Teladoc (TDOC) Reports Q2 Loss, Misses Revenue Estimates

Shares of Teladoc Health Inc. fell more than 15% in the extended session Wednesday after the once high-flying telehealth company posted a much larger-than-expected quarterly loss and withdrew its guidance for the year.

Teladoc posts another quarterly loss, and online mental-health unit sees revenue slip

Telehealth company Teladoc Health Inc TDOC reported second-quarter financial results after market close Wednesday.

Teladoc Stock Falls Below 52-Week Lows On Q2 Earnings: Guidance Withdrawn On BetterHealth Weakness, 'Focused On Addressing The Work Ahead Of Us With Urgency'

PURCHASE, NY, July 31, 2024 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE: TDOC), the global leader in whole-person virtual care, today reported financial results for the three months ended June 30, 2024 (“Second Quarter 2024”). Unless otherwise noted, percentage and other changes are relative to the three months ended June 30, 2023 (“Second Quarter 2023”).

Teladoc Health Reports Second Quarter 2024 Results

Teladoc's (TDOC) second-quarter results are likely to reflect lower advertising and marketing expenses.

Can Teladoc (TDOC) Q2 Earnings Navigate BetterHelp Profit Woes?

Beyond analysts' top -and-bottom-line estimates for Teladoc (TDOC), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2024.

Countdown to Teladoc (TDOC) Q2 Earnings: Wall Street Forecasts for Key Metrics

Virtual healthcare provider Teladoc Health Inc. NYSE: TDOC stock is trading down 57.8% year-to-date (YTD). The collapse occurred after reporting Q4 2023 earnings, which were further accelerated by its Q1 2024 earnings miss and lowered guidance.

Can the New CEO Revive This Struggling Telehealth Stock?

Teladoc (TDOC) closed the most recent trading day at $9.30, moving +1.2% from the previous trading session.

Teladoc (TDOC) Ascends While Market Falls: Some Facts to Note

I no longer believe it makes sense to sustain a bearish outlook on Teladoc, as its current valuation already reflects many negative aspects. At approximately 5x next year's free cash flow, Teladoc presents a better risk-reward profile than it has in quite some time. Teladoc's balance sheet, while not flawless, is manageable and can be improved with focused efforts.

Teladoc's Vital Signs: Why 5x FCF Means Stable Health (Rating Upgrade)

Onto Innovation

Palantir Technologies

Tech stocks got you down? While weeks of institutional tech stock outflows indicated souring sentiment, this week's tech sector “crash” — though due for a correction, considering its current concentration — only trades a few points below recent highs.

3 Tech Stocks That Could Grow Your Wealth

PURCHASE, NY, July 17, 2024 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE: TDOC), the global leader in whole-person virtual care, announced that it will release second quarter 2024 results on Wednesday, July 31, 2024, after the market closes. In conjunction, the company will host a conference call to review results at 4:30 p.m. E.T. on the same day.

Teladoc Health to Announce Second Quarter 2024 Financial Results

NEW YORK, July 16, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Teladoc Health, Inc. ("Teladoc" or the "Company") (NYSE: TDOC) of a class action securities lawsuit.

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 16, 2024 in Teladoc Health, Inc. Lawsuit – TDOC

Health Catalyst Inc

LifeMD 

Healthcare portfolios include telehealth stocks, notably after the COVID-19 pandemic, which increased global telemedicine usage, demonstrating their importance for lockdowns and other social isolation scenarios. The worldwide telehealth market was $122.2 billion in 2023 and is anticipated to rise 28.4% annually from 2024 to 2032.

3 Overlooked Telehealth Stocks Poised for a Comeback

NEW YORK, NY / ACCESSWIRE / July 15, 2024 / If you suffered a loss on your Teladoc Health, Inc. (NYSE:TDOC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/teladoc-health-inc-lawsuit-submission-form?prid=90794&wire=1 or contact Joseph E. Levi, Esq.

Shareholders of Teladoc Health, Inc. Should Contact Levi & Korsinsky Before July 16, 2024 to Discuss Your Rights - TDOC

Investors can contact the law firm at no cost to learn more about recovering their losses

Teladoc Health, Inc. Investors: Class action lawsuit filed on behalf of investors; the Portnoy Law Firm

NEW YORK, NY / ACCESSWIRE / July 15, 2024 / If you suffered a loss on your Teladoc Health, Inc. (NYSE:TDOC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/teladoc-health-inc-lawsuit-submission-form?prid=90767&wire=1 or contact Joseph E. Levi, Esq.

Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Teladoc Health, Inc.(TDOC) Shareholders

NEW YORK, July 15, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of stock of Teladoc Health, Inc. (NYSE: TDOC) between November 2, 2022 and February 20, 2024, both dates inclusive (the “Class Period”), of the important July 16, 2024 lead plaintiff deadline.

TDOC IMPORTANT DEADLINE: ROSEN, A TOP RANKED LAW FIRM, Encourages Teladoc Health, Inc. Investors to Secure Counsel Before Important July 16 Deadline in Securities Class Action – TDOC

NEW YORK, July 15, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Teladoc Health, Inc. (NYSE: TDOC).

Lost Money on Teladoc Health, Inc.(TDOC)? Join Class Action Suit Seeking Recovery – Contact The Gross Law Firm

NEW YORK , July 15, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Teladoc Health, Inc. ("Teladoc" or the "Company") (NYSE: TDOC) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Teladoc investors who were adversely affected by alleged securities fraud between November 2, 2022 and February 20, 2024.

Levi & Korsinsky Reminds Teladoc Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 16, 2024 - TDOC

NEW YORK, July 15, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Teladoc Health, Inc. (“Teladoc” or “the Company”) (NYSE: TDOC) and certain of its officers.

TDOC INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Teladoc Health, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

NEW YORK, NY / ACCESSWIRE / July 14, 2024 / If you suffered a loss on your Teladoc Health, Inc. (NYSE:TDOC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/teladoc-health-inc-lawsuit-submission-form?prid=90669&wire=1 or contact Joseph E. Levi, Esq.

Teladoc Health, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before July 16, 2024 to Discuss Your Rights - TDOC

NEW YORK, NY / ACCESSWIRE / July 14, 2024 / Pomerantz LLP announces that a class action lawsuit has been filed against Teladoc Health Inc. ("Teladoc" or the "Company") (NYSE:TDOC). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.

SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Teladoc Health Inc. – TDOC

DexCom

Investors are showing varying degrees of appetite for the telehealth and diabetes care industries. Teladoc has undergone major changes in recent years, and investors are warily eyeing its path forward.

News for Teladoc Stock (TDOC)